Mechanisms of statin-mediated inhibition of small G-protein function

被引:191
作者
Cordle, A [1 ]
Koenigsknecht-Talboo, J [1 ]
Wilkinson, B [1 ]
Limpert, A [1 ]
Landreth, G [1 ]
机构
[1] Case Western Reserve Univ, Sch Med, Dept Neurosci, Cleveland, OH 44106 USA
关键词
D O I
10.1074/jbc.M505268200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have been reported to reduce the risk of Alzheimer disease. We have shown previously that statins inhibit a beta-amyloid (A beta)mediated inflammatory response through mechanisms independent of cholesterol reduction. Specifically, statins exert anti-inflammatory actions through their ability to prevent the isoprenylation of members of the Rho family of small G-proteins, resulting in the functional inactivation of these G-proteins. We report that statin treatment of microglia results in perturbation of the cytoskeleton and morphological changes due to alteration in Rho family function. Statins also block A beta-stimulated phagocytosis through inhibition of Rac action. Paradoxically, the statin-mediated inactivation of G-protein function was associated with increased GTP loading of Rac and RhoA, and this effect was observed in myeloid lineage cells and other cell types. Statin treatment disrupted the interaction of Rac with its negative regulator the Rho guanine nucleotide dissociation inhibitor ( RhoGDI), an interaction that is dependent on protein isoprenylation. We propose that lack of negative regulation accounts for the increased GTP loading. Isoprenylation of Rac is also required for efficient interaction with the plasma membrane, and we report that statin treatment dramatically reduces the capacity of Rac to interact with membranes. These results suggest amechanism by which statins inhibit the actions of Rho GTPases and attenuate A beta-stimulated inflammation.
引用
收藏
页码:34202 / 34209
页数:8
相关论文
共 65 条
  • [1] Inflammation and Alzheimer's disease
    Akiyama, H
    Barger, S
    Barnum, S
    Bradt, B
    Bauer, J
    Cole, GM
    Cooper, NR
    Eikelenboom, P
    Emmerling, M
    Fiebich, BL
    Finch, CE
    Frautschy, S
    Griffin, WST
    Hampel, H
    Hull, M
    Landreth, G
    Lue, LF
    Mrak, R
    Mackenzie, IR
    McGeer, PL
    O'Banion, MK
    Pachter, J
    Pasinetti, G
    Plata-Salaman, C
    Rogers, J
    Rydel, R
    Shen, Y
    Streit, W
    Strohmeyer, R
    Tooyoma, I
    Van Muiswinkel, FL
    Veerhuis, R
    Walker, D
    Webster, S
    Wegrzyniak, B
    Wenk, G
    Wyss-Coray, T
    [J]. NEUROBIOLOGY OF AGING, 2000, 21 (03) : 383 - 421
  • [2] Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease
    Bard, F
    Cannon, C
    Barbour, R
    Burke, RL
    Games, D
    Grajeda, H
    Guido, T
    Hu, K
    Huang, JP
    Johnson-Wood, K
    Khan, K
    Kholodenko, D
    Lee, M
    Lieberburg, I
    Motter, R
    Nguyen, M
    Soriano, F
    Vasquez, N
    Weiss, K
    Welch, B
    Seubert, P
    Schenk, D
    Yednock, T
    [J]. NATURE MEDICINE, 2000, 6 (08) : 916 - 919
  • [3] Inhibition of geranylgeranylation mediates the effects of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors on microglia
    Bi, XN
    Baudry, M
    Liu, JH
    Yao, YQ
    Fu, L
    Brucher, F
    Lynch, G
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (46) : 48238 - 48245
  • [4] 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation
    Blanco-Colio, LM
    Villa, A
    Ortego, M
    Hernández-Presa, MA
    Pascual, A
    Plaza, JJ
    Egido, J
    [J]. ATHEROSCLEROSIS, 2002, 161 (01) : 17 - 26
  • [5] Bodovitz S, 1996, J BIOL CHEM, V271, P4436
  • [6] BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
  • [7] BURDICK D, 1992, J BIOL CHEM, V267, P546
  • [8] Cholesterol in Alzheimer's disease and tauopathy
    Burns, M
    Duff, K
    [J]. ALZHEIMER'S DISEASE: VASCULAR ETIOLOGY AND PATHOLOGY, 2002, 977 : 367 - 375
  • [9] Pharmacological concentrations of the HMG-CoA reductase inhibitor lovastatin decrease the formation of the Alzheimer β-amyloid peptide in vitro and in patients
    Buxbaum, JD
    Cullen, EI
    Friedhoff, LT
    [J]. FRONTIERS IN BIOSCIENCE, 2002, 7 : A50 - A59
  • [10] Do statins slow down Alzheimer's disease? A review
    Caballero, J
    Nahata, M
    [J]. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2004, 29 (03) : 209 - 213